Role of advanced glycation end product receptors in the pathogenesis of diabetic retinopathy

Journal of Diabetes and its Complications

Volumn 25, Issue 3, 2011, Pages 168-174

  Al Mesallamy, Hala O ^a   Hammad, Lamiaa N ^b   El Mamoun, Tarek A ^c   Khalil, Basma M ^b  

^a Ain Shams University   (Egypt)

^b Egypt   (Egypt)

^c AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

AGEs; DR; NO; sRAGE; sVCAM 1

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; NITRIC OXIDE; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; PROGNOSIS; RECEPTORS, IMMUNOLOGIC; SEVERITY OF ILLNESS INDEX; VASCULAR CELL ADHESION MOLECULE-1;

EID: 79955066389     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2010.06.005     Document Type: Article

References (33)

1. Aiello L.M. Perspectives on diabetic retinopathy American Journal of Ophthalmology 136 1 2003 122 135 (Pubitemid 36794505)
2. Anitha B., Sampathkumar R., Balasubramanyam M., and Rema M. Advanced glycation index and its association with severity of diabetic retinopathy in type 2 diabetic subjects Journal of Diabetes and Its Complication 22 2008 261 266 (Pubitemid 351885489)
3. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications Atherosclerosis 196 2008 9 21
4. Caldwell R.B., Zhang W., Romero M.J., and Caldwell R.W. Vascular dysfunction in retinopathy: an emerging role for arginase Brain Research Bulletin 81 2010 303 309
5. Cheung N., and Wong T.Y. Diabetic retinopathy and systemic vascular complications Progress in Retinal and Eye Research 27 2008 161 176
6. Ciulla T.A., Amador A.G., and Zinman B. Diabetic retinopathy and diabetic macular edema pathophysiology, screening, and novel therapies Diabetes Care 29 2003 2653 2663
7. Du X., Matsumura T., Edelstein D., Rossetti L., Zsengeller Z., Szabo C., and Brownlee M. Inhibition of GAPDH activity by poly (ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells Journal of Clinical Investigation 112 2003 1049-1057
8. Fong D.S., Aiello L., and Gardner T.W. American Diabetes Association. Diabetic retinopathy Diabetes Care 26 2003 226 229
9. Gohda T., Tanimoto M., Moon J-Y., Gotoh H., Aoki T., Matsumoto M., Shibata T., Ohsawa I., Funabiki K., and Tomino Y. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function Diabetes Research and Clinical Practice 81 2008 196 201
10. Grossin N., Wautier M.-P., Measb T., Guillausseau P.-J., Massin P., and Wautier J.-L. Severity of diabetic microvascular complications is associated with a low soluble RAGE level Diabetes & Metabolism 34 2008 392 395
11. Harhaj N.S., and Antonetti D.A. Regulation of tight junctions and loss of barrier function in pathophysiology International Journal of Biochemistry and Cell Biology 36 2004 1206 1237 (Pubitemid 38519069)
12. Katakami N., Matsuhisa M., Kaneto H., Matsuoka T., Sakamoto K., Yasuda T., Umayaharab Y., Kosugib K., and Yamasaki Y. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes Atherosclerosis 204 2009 288 292
13. Kowluru R.A., and Chan P.S. Oxidative stress and diabetic retinopathy Experimental Diabetes Research 2007 2007 1 14
14. Lapolla A., Traldi P., and Fedele D. Importance of measuring products of non-enzymatic glycation of proteins Clinical Biochemistry 38 2005 103 115 (Pubitemid 40092452)
15. Lindsey J.B., Cipollone F., Abdullah S.M., and McGuire D.K. Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications Diabetes and Vascular Disease Research 6 2009 7 14
16. Miura J., Uchigata Y., Yamamoto Y., Takeuchi M., Sakurai S., Watanabe T., Yonekura H., Yamagishi S.-I., Makita Z., Sato A., Omori Y., Yamamoto H., and Iwamoto Y. AGE down-regulation of monocyte RAGE expression and its association with diabetic complications in type 1 diabetes Journal of Diabetes and Its Complications 18 2004 53 59 (Pubitemid 38332952)
17. Mohamed Q., Gillies M.C., and Wong T.Y. Management of diabetic retinopathy: a systematic review JAMA 298 2007 902 916 (Pubitemid 47311296)
18. Motiejunaite R., and Kazlauskas A. Pericytes and ocular diseases Experimental Eye Research 86 2008 171 177
19. Nakamura K., Yamagishi S., Adachi H., Matsui T., Nakamura Y.K., Takeuchi M., Inoue H., and Imaizumi T. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes Microvascular Research 76 2008 52 56
20. Nessar A. Advanced glycation endproducts-role in pathology of diabetic complications Diabetes Research and Clinical Practice 67 2005 3 21
21. Orasanu G., and Plutzky J. The pathologic continuum of diabetic vascular disease Journal of the American College of Cardiology 53 2009 S35 S42
22. Park K.S., Kim S.S., Kim J.C., Kim H.C., Im Y.S., Ahn C.W., and Lee H.K. Serum and tear levels of nerve growth factor in diabetic retinopathy patients American Journal of Opthalmology, 145, 432- 2008 437
23. Pereira E.C., Ferderbar S., Bertolami M.C., Faludi A.A., Monte O., Xavier H.T., Pereira T.V., and Abdalla D.S. Biomarkers of oxidative stress and endothelial dysfunction in glucose intolerance and diabetes mellitus Clinical Biochemistry 41 2008 1454 1460
24. Sakurai S., Yamamoto Y., Tamei H., Matsuki H., Obata K., Hui L., Miura J., Osawa M., Uchigata Y., Iwamoto Y., Watanabe T., Yonekura H., and Yamamoto H. Development of an ELISA for esRAGE and its application to type 1 diabetic patients Diabetes Research and Clinical Practice 73 2006 158 165 (Pubitemid 43928158)
25. Schalkwijk C.G., and Stehouwer C.D. Vascular complications in diabetes mellitus: the role of endothelial dysfunction Clinical Science 109 2005 143 159 (Pubitemid 41117297)
26. Siemianowicz K., Francuz T., Gminski J., Telega A., and Syzd M. Endothelium dysfunction markers in patients with diabetic retinopathy International Journal of Molecular Medicine 15 2005 459 462
27. Snow V., Weiss K.B., and Mottur-Pilson C. The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus Annals of International Medicine 138 2003 587 592 (Pubitemid 38124681)
28. Sulochana K.N., Ramakrishnan S., Rajesh M., Coral K., and Badrinath S.S. Diabetic retinopathy: molecular mechanisms, present regime of treatment and future perspectives Current Science 80 2 2001 1 25
29. Trinder P Determination of blood glucose using 4-aminophenazone as oxygen acceptor Journal of Clinical Pathology 22 1969 246
30. Yamagishi S., Matsui T., Nakamura K., Inoue H., Takeuchi M., Ueda S., Fukami K., Okuda S., and Imaizumi T. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression Microvascular Research 75 2008 130 134 (Pubitemid 350266734)
31. Yokoi M., Yamagishi S., Takeuchi M., Matsui T., Yoshida Y., and Ohgami K. Positive correlation between vitreous levels of advanced glycation end products and vascular endothelial growth factor in patients with diabetic retinopathy sufficiently treated with photocoagulation British Journal of Ophthalmology 91 2007 397 405
32. Yonekura H., Yamamoto Y., Sakurai S., Petrova R.G., Abedin J., Li H., Yasui K., Takeuchi M., Makita M., Takasawa S., Okamoto H., Watanabe T., and Yamamoto H. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes induced vascular injury Biochemical Journal 370 2003 1097 1109 (Pubitemid 36399105)
33. Yonem A., Duran C., Unal M., Ipcioglu O.M., and Ozcan O. Plasma apelin and asymmetric dimethylarginine levels in type 2 diabetic patients with diabetic retinopathy Diabetes Research and Clinical Practice 84 2009 219 223